Summary
We're thrilled to share the exciting news of launching our inaugural affiliate in the UK! Our decision to expand into the UK is driven by multiple factors:
Over recent years, we've observed that the UK, despite Brexit, continues to be a highly appealing destination for medical research.
With world-renowned centers of medical innovation like University of Cambridge and University of Oxford, many of our clients are either based in the UK or have significant operations there.
At iliomad Health Data , our mission is to support our clients in the best possible locations, and the UK certainly provides an excellent setting for this.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Scientific Research and the GDPR: Challenges and Opportunities in Secondary Data Use
Turning clinical trial data into tomorrow’s breakthroughs isn’t just science—it’s law. We explore GDPR roadblocks, secondary use challenges, and the UK’s bold new approach.
Data Protection Strategies for Phase III Clinical Trials
Phase III clinical trials require strict compliance with privacy and data protection laws across multiple jurisdictions, including GDPR obligations, local authorizations, and ethics committee oversight. The article outlines practical strategies such as the “funnel approach” to harmonize global frameworks, manage cross-border transfers, appoint Data Protection Officers, and ensure proper informed consent documentation. It also emphasizes the need for local representatives, jurisdiction-specific formalities, and standardized templates to maintain compliance and avoid delays in global studies.
Addressing the Data Protection and Ethical Challenges posed by AI in Health – Part 2
Our latest analysis: U.S. vs EU—AI regulation shaping healthcare’s future.
